Literature DB >> 17363583

Genome-wide loss of heterozygosity and copy number analysis in melanoma using high-density single-nucleotide polymorphism arrays.

Mitchell Stark1, Nicholas Hayward.   

Abstract

Although a number of genes related to melanoma development have been identified through candidate gene screening approaches, few studies have attempted to conduct such analyses on a genome-wide scale. Here we use Illumina 317K whole-genome single-nucleotide polymorphism arrays to define a comprehensive allelotype of melanoma based on loss of heterozygosity (LOH) and copy number changes in a panel of 76 melanoma cell lines. In keeping with previous reports, we found frequent LOH on chromosome arms 9p (72%), 10p (55%), 10q (55%), 9q (49%), 6q (43%), 11q (43%), and 17p (41%). Tumor suppressor genes (TSGs) can be identified through homozygous deletion (HD). We detected 174 HDs, the most common of which targeted CDKN2A (n = 33). The second highest frequency of HD occurred in PTEN (n = 8), another well known melanoma TSG. HDs were also common for PTPRD (n = 7) and HDAC4 (n = 3), TSGs recently found to be mutated or deleted in other cancer types. Analysis of other HDs and regions of LOH that we have identified might lead to the characterization of further melanoma TSGs. We noted 197 regional amplifications, including some centered on the melanoma oncogenes MITF (n = 9), NRAS (n = 3), BRAF (n = 3), and CCND1 (n = 3). Other amplifications potentially target novel oncogenes important in the development of a subset of melanomas. The numerous focal amplifications and HDs we have documented here are the first step toward identifying a comprehensive catalog of genes involved in melanoma development, some of which may be useful prognostic markers or targets for therapies to treat this disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17363583     DOI: 10.1158/0008-5472.CAN-06-4152

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  87 in total

Review 1.  Delving into somatic variation in sporadic melanoma.

Authors:  Vijay Walia; Euphemia W Mu; Jimmy C Lin; Yardena Samuels
Journal:  Pigment Cell Melanoma Res       Date:  2012-02-13       Impact factor: 4.693

Review 2.  From genes to drugs: targeted strategies for melanoma.

Authors:  Keith T Flaherty; F Stephen Hodi; David E Fisher
Journal:  Nat Rev Cancer       Date:  2012-04-05       Impact factor: 60.716

Review 3.  Microarray Techniques to Analyze Copy-Number Alterations in Genomic DNA: Array Comparative Genomic Hybridization and Single-Nucleotide Polymorphism Array.

Authors:  Károly Szuhai; Maarten Vermeer
Journal:  J Invest Dermatol       Date:  2015-10       Impact factor: 8.551

4.  Ataxia telangiectasia mutated (ATM) inhibition transforms human mammary gland epithelial cells.

Authors:  Stefano J Mandriota; Raphaële Buser; Laurence Lesne; Christelle Stouder; Vincent Favaudon; Pierre Maechler; Frédérique Béna; Virginie Clément; Curzio Rüegg; Roberto Montesano; André-Pascal Sappino
Journal:  J Biol Chem       Date:  2010-02-22       Impact factor: 5.157

5.  Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436).

Authors:  Katherine L Nathanson; Anne-Marie Martin; Bradley Wubbenhorst; Joel Greshock; Richard Letrero; Kurt D'Andrea; Steven O'Day; Jeffrey R Infante; Gerald S Falchook; Hendrik-Tobias Arkenau; Michael Millward; Michael P Brown; Anna Pavlick; Michael A Davies; Bo Ma; Robert Gagnon; Martin Curtis; Peter F Lebowitz; Richard Kefford; Georgina V Long
Journal:  Clin Cancer Res       Date:  2013-07-05       Impact factor: 12.531

6.  Mutational inactivation of PTPRD in glioblastoma multiforme and malignant melanoma.

Authors:  David A Solomon; Jung-Sik Kim; Julia C Cronin; Zita Sibenaller; Timothy Ryken; Steven A Rosenberg; Habtom Ressom; Walter Jean; Darell Bigner; Hai Yan; Yardena Samuels; Todd Waldman
Journal:  Cancer Res       Date:  2008-12-15       Impact factor: 12.701

7.  Integrated analysis of homozygous deletions, focal amplifications, and sequence alterations in breast and colorectal cancers.

Authors:  Rebecca J Leary; Jimmy C Lin; Jordan Cummins; Simina Boca; Laura D Wood; D Williams Parsons; Siân Jones; Tobias Sjöblom; Ben-Ho Park; Ramon Parsons; Joseph Willis; Dawn Dawson; James K V Willson; Tatiana Nikolskaya; Yuri Nikolsky; Levy Kopelovich; Nick Papadopoulos; Len A Pennacchio; Tian-Li Wang; Sanford D Markowitz; Giovanni Parmigiani; Kenneth W Kinzler; Bert Vogelstein; Victor E Velculescu
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-13       Impact factor: 11.205

8.  Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis.

Authors:  Tiffany J Parmenter; Margarete Kleinschmidt; Kathryn M Kinross; Simon T Bond; Jason Li; Mohan R Kaadige; Aparna Rao; Karen E Sheppard; Willy Hugo; Gulietta M Pupo; Richard B Pearson; Sean L McGee; Georgina V Long; Richard A Scolyer; Helen Rizos; Roger S Lo; Carleen Cullinane; Donald E Ayer; Antoni Ribas; Ricky W Johnstone; Rodney J Hicks; Grant A McArthur
Journal:  Cancer Discov       Date:  2014-01-27       Impact factor: 39.397

9.  Integrative genome comparison of primary and metastatic melanomas.

Authors:  Omar Kabbarah; Cristina Nogueira; Bin Feng; Rosalynn M Nazarian; Marcus Bosenberg; Min Wu; Kenneth L Scott; Lawrence N Kwong; Yonghong Xiao; Carlos Cordon-Cardo; Scott R Granter; Sridhar Ramaswamy; Todd Golub; Lyn M Duncan; Stephan N Wagner; Cameron Brennan; Lynda Chin
Journal:  PLoS One       Date:  2010-05-24       Impact factor: 3.240

10.  GeneSet2miRNA: finding the signature of cooperative miRNA activities in the gene lists.

Authors:  Alexey V Antonov; Sabine Dietmann; Philip Wong; Dominik Lutter; Hans W Mewes
Journal:  Nucleic Acids Res       Date:  2009-05-06       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.